New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSelank vs PNC-27

Selank vs PNC-27

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
Selank
Immune Support
PNC-27
Summary
Selank is a synthetic heptapeptide analog of tuftsin developed in Russia. It is a potent anxiolytic that reduces anxiety and enhances cognitive function without sedation or addiction. It is approved for clinical use in Russia for anxiety disorders.
PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
Half-Life
Minutes (but effects persist for hours)
Not well established; estimated minutes to hours
Admin Route
SubQ, Intranasal
Intravenous (research), Intraperitoneal (research)
Research
Typical Dose
250–500 mcg
Not established for humans; research doses vary by cell line and model
Frequency
1–3 times daily
Not established for human use
Key Benefits
  • Reduces anxiety without sedation
  • Enhances memory and learning
  • Improves focus and concentration
  • Stabilizes mood
  • Reduces physiological stress response
  • May enhance motivation
  • No addiction potential or withdrawal
  • Fast-acting — effects within 20–30 minutes
  • Approved clinically in Russia for anxiety disorders
  • Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
  • Spares normal cells lacking surface HDM2 expression
  • Membranolytic mechanism bypasses intracellular resistance pathways
  • Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
  • Potential for combination with conventional chemotherapy
  • Novel non-genotoxic anticancer mechanism
Side Effects
  • Mild sedation at higher doses (paradoxical)
  • Fatigue (rare)
  • Irritability during discontinuation (uncommon)
  • Limited human clinical data; largely in vitro and animal studies
  • Potential immunogenic reactions (foreign peptide)
  • Systemic toxicity at high doses not well characterized
  • Unknown interactions with current chemotherapy agents
Stacks With